Discover

LSTA
Lisata Therapeutics, Inc.
1.06
1 x 1.17
1 x 1.26
bid
ask
-
0.14
11.67%
1 @ 04:00 PM
1.06 +0.00 (0.00%)
Ytd-43.01%
1y-56.38%
1.02
day range
1.28
0.99
52 week range
5.04
Open1.28Prev Close1.20Low1.02High1.28Mkt Cap11.45M
Vol280.23KAvg Vol302.71KEPS-1.46P/EN/AForward P/E-1.20
Beta1.22Short Ratio1.79Inst. Own9.07%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg1.41200-d Avg3.071yr Est14.00

LSTA News

Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)
defenseworld.net
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) and GeoVax Labs (NASDAQ: GOVX - Get Free Report

Lisata Therapeutics wins new US patent for pancreatic cancer drug
proactiveinvestors.com
Lisata Therapeutics wins new US patent for pancreatic cancer drug

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experim

Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
globenewswire.com
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of P

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“L

Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
proactiveinvestors.com
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first pat

benzinga.com
Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 Fo

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
globenewswire.com
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Cl

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA
gurufocus.com
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVAPR NewswireNE

Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
proactiveinvestors.com
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions

Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from t

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
globenewswire.com
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentati

SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics,

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
benzinga.com
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata Therapeutics, Inc. (NASDAQ:LSTA) on Thursday announced it has acquired clinical-stage biotech

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
benzinga.com
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Ph

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular ses

Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
proactiveinvestors.com
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage bio

benzinga.com
Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
globenewswire.com
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's

Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
proactiveinvestors.com
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed

Two of the biggest listings in market history are queued up for the back end of this year, and punte

Lisata Therapeutics moves forward with legal action following Kuva merger termination
proactiveinvestors.com
Lisata Therapeutics moves forward with legal action following Kuva merger termination

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action followin

benzinga.com
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts A

Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previ

Lisata Therapeutics Provides Update Following Termination of Merger Agreement
globenewswire.com
Lisata Therapeutics Provides Update Following Termination of Merger Agreement

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market

Lisata Therapeutics Stock Falls After Hours: Here's Why
benzinga.com
Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics stock fell after hours after updating investors on its pending acquisition and t

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's afte

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
globenewswire.com
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisitio

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeuti

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
newsfilecorp.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announce

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
proactiveinvestors.com
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs

benzinga.com
Kuva Acquisition Commences Tender Offer To Purchase All Issued And Outstanding Shares Of Common Stoc

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
globenewswire.com
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
proactiveinvestors.com
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs

Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
globenewswire.com
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Sharehold

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

benzinga.com
Reported Friday, Lisata Therapeutics To Be Taken Private By Kuva Labs In A Deal Offering Stockholder

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent va

What Does the Market Think About Lisata Therapeutics Inc?
benzinga.com
What Does the Market Think About Lisata Therapeutics Inc?

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
Lisata Therapeutics, Qilu Pharmaceutical Mutually Terminate 2021 License And Collaboration Agreement

Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-sta

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates
benzinga.com
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Why Is Lisata Therapeutics Stock Gaining Today?
benzinga.com
Why Is Lisata Therapeutics Stock Gaining Today?

Lisata Therapeutics shares surged premarket after Kuva Labs agreed to acquire the company for $4 per

Dow Surges 300 Points; Netflix Shares Fall After Q4 Results
benzinga.com
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results

benzinga.com
Lisata Therapeutics To Be Acquired By Kuva Labs In $4.00/Share Tender Offer

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
Lisata Therapeutics Q3 EPS $(0.49) Beats $(0.61) Estimate

Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.49) per share which beat the anal

Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For November 6, 2025

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Lisata Therapeutics Releases Preclinical Data Showing That Lisata's Proprietary iRGD Cyclic Peptide,

Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stag